Browne L Daniel 4
4 · Revance Therapeutics, Inc. · Filed Jul 3, 2018
Insider Transaction Report
Form 4
Browne L Daniel
DirectorCEO and President
Transactions
- Other
Common Stock
2018-06-29$23.33/sh+668$15,586→ 142,543 total
Holdings
- 409(indirect: See footnote)
Common Stock
Footnotes (2)
- [F1]These shares were acquired by Mr. Browne under the Issuer's 2014 Employee Stock Purchase Plan (the "Plan") on June 29, 2018 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Mr. Browne purchased the maximum number of shares allowable under the Issuer's Plan and Internal Revenue Code Section 423(b)(8) for 2018.
- [F2]These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.